Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance

Journal of Hepatology

Volumn 63, Issue 5, 2015, Pages 1103-1110

  O'Brien, Thomas R ^a   Pfeiffer, Ruth M ^a   Paquin, Ashley ^a   Lang Kuhs, Krystle A ^a   Chen, Sabrina ^b   Bonkovsky, Herbert L ^c   Edlin, Brian R ^d   Howell, Charles D ^e   Kirk, Gregory D ^f   Kuniholm, Mark H ^g   Morgan, Timothy R ^h   Strickler, Howard D ^g   Thomas, David L ^f   Prokunina Olsson, Ludmila ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

^c LEVINE CANCER INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Genetics; IFNL3; IFNL4; IL28B; Innate immunity; Interferon lambda; Treatment; Viral clearance

Indexed keywords

INTERFERON; INTERFERON LAMBDA 3; INTERFERON LAMBDA 4; MESSENGER RNA; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

3' UNTRANSLATED REGION; ADULT; AFRICAN AMERICAN; ALLELE; ANTIVIRAL THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RESPONSE; EUROPEAN AMERICAN; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETREATMENT; RNA STABILITY; TREATMENT RESPONSE; VIRAL CLEARANCE; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM;

ALLELES; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RNA, VIRAL;

EID: 84943650678     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.06.035     Document Type: Conference Paper

References (43)

1. S.V. Kotenko, G. Gallagher, V.V. Baurin, A. Lewis-Antes, M. Shen, N.K. Shah, and et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat Immunol 4 2003 69 77
2. P. Sheppard, W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, T.E. Whitmore, and et al. IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 4 2003 63 68
3. B.A. Fox, P.O. Sheppard, and P.J. O'Hara The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family PLoS One 4 2009 e4933
4. L. Prokunina-Olsson, B. Muchmore, W. Tang, R.M. Pfeiffer, H. Park, H. Dickensheets, and et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Nat Genet 45 2013 164 171
5. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, and et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
6. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, and et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
7. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, and et al. Genome-wide association of IL28B with response to pegylated interferon-[alpha] and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
8. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, C. O'Huigin, and et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
9. A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. Di Iulio, T. Mueller, and et al. Genetic variation in IL28B Is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345
10. S. Bibert, T. Roger, T. Calandra, M. Bochud, A. Cerny, N. Semmo, and et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction J Exp Med 210 2013 1109 1116
11. S. Franco, E. Aparicio, M. Parera, B. Clotet, C. Tural, and M.A. Martinez IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients AIDS 28 2014 133 136
12. A.P. McFarland, S.M. Horner, A. Jarret, R.C. Joslyn, E. Bindewald, B.A. Shapiro, and et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs Nat Immunol 15 2014 72 79
13. S. Kulkarni, R. Savan, Y. Qi, X. Gao, Y. Yuki, S.E. Bass, and et al. Differential microRNA regulation of HLA-C expression and its association with HIV control Nature 472 2011 495 498
14. L.F. Thomas, and P. Sætrom Single nucleotide polymorphisms can create alternative polyadenylation signals and affect gene expression through loss of microRNA-regulation PLoS Comput Biol 8 2012 e1002621
15. H.S. Conjeevaram, M.W. Fried, L.J. Jeffers, N.A. Terrault, T.E. Wiley-Lucas, N. Afdhal, and et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131 2006 470 477
16. A.M. Di Bisceglie, M.L. Shiffman, G.T. Everson, K.L. Lindsay, J.E. Everhart, E.C. Wright, and et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
17. W.M. Lee, J.L. Dienstag, K.L. Lindsay, A.S. Lok, H.L. Bonkovsky, M.L. Shiffman, and et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders Control Clin Trials 25 2004 472 492
18. P.V. Aka, M.H. Kuniholm, R.M. Pfeiffer, A.S. Wang, W. Tang, S. Chen, and et al. Association of the IFNL4-ΔG allele with impaired spontaneous clearance of hepatitis C virus J Infect Dis 209 2014 350 354
19. D. Vlahov, J.C. Anthony, A. Munoz, J. Margolick, K.E. Nelson, D.D. Celentano, and et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants NIDA Res Monogr 109 1991 75 100
20. J.K. Watters, R.N. Bluthenthal, and A.H. Kral HIV seroprevalence in injection drug users JAMA 273 1995 1178
21. F.C. Tseng, T.R. O'Brien, M. Zhang, A.H. Kral, B.A. Ortiz-Conde, J. Lorvick, and et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000 Hepatology 46 2007 666 671
22. M.C. Bacon, V. von Wyl, C. Alden, G. Sharp, E. Robison, N. Hessol, and et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench Clin Diagn Lab Immunol 12 2005 1013 1019
23. E.G. Meissner, D. Wu, A. Osinusi, D. Bon, K. Virtaneva, D. Sturdevant, and et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome J Clin Invest 124 2014
24. J.H. Hoofnagle, A.S. Wahed, R.S. Brown, C.D. Howell, and S.H. Bellw Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection J Infect Dis 199 2009 1112 1120
25. J.C. Barrett, B. Fry, J. Maller, and M.J. Daly Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 2005 263 265
26. M.S. Pepe The statistical evaluation of medical tests for classification and prediction 2003 Oxford University Press Oxford
27. M. de Castellarnau, E. Aparicio, M. Parera, S. Franco, C. Tural, B. Clotet, and et al. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients PLoS One 7 2012 e31016
28. V. Pedergnana, M. Abdel-Hamid, J. Guergnon, A. Mohsen, L. Le Fouler, I. Theodorou, and et al. Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus PLoS One 7 2012 e38578
29. E. Terczyńska-Dyla, S. Bibert, F.H.T. Duong, I. Krol, S. Jørgensen, E. Collinet, and et al. Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes Nat Commun 5 2014 5699
30. E. Galmozzi, and A. Aghemo Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients J Clin Virol 59 2014 274 275
31. F.M. Key, B. Peter, M.Y. Dennis, E. Huerta-Sánchez, W. Tang, L. Prokunina-Olsson, and et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4) PLoS Genet 10 2014 e1004681
32. J. Manry, G. Laval, E. Patin, S. Fornarino, Y. Itan, M. Fumagalli, and et al. Evolutionary genetic dissection of human interferons J Exp Med 208 2011 2747 2759
33. T.R. O'Brien, L. Prokunina-Olsson, and R.P. Donnelly IFN-λ4: the paradoxical new member of the interferon lambda family J Interferon Cytokine Res 34 2014 829 838
34. O.J. Hamming, E. Terczyńska-Dyla, G. Vieyres, R. Dijkman, S.E. Jørgensen, H. Akhtar, and et al. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses EMBO J 32 2013 3055 3065
35. J.H. Hoofnagle, and A.H. Sherker Therapy for hepatitis C - the costs of success N Engl J Med 370 2014 1552 1553
36. A.F. Stättermayer, T. Scherzer, S. Beinhardt, K. Rutter, H. Hofer, and P. Ferenci Review article: genetic factors that modify the outcome of viral hepatitis Aliment Pharmacol Ther 39 2014 1059 1070
37. E.G. Meissner, D. Bon, L. Prokunina-Olsson, W. Tang, H. Masur, T.R. O'Brien, and et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin J Infect Dis 209 2014 1700 1704
38. S. Zeuzem, V. Soriano, T. Asselah, J.-P. Bronowicki, A.W. Lohse, B. Mullhaupt, and et al. Faldaprevir and deleobuvir for HCV genotype 1 infection N Engl J Med 369 2013 630 639
39. T.R. O'Brien, K.A. Lang Kuhs, and R.M. Pfeiffer Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C Open Forum Infect Dis 1 2014
40. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, E. Lawitz, and et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
41. T.R. O'Brien, and R.M. Pfeiffer Reply: subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C Open Forum Infect Dis 2 2015
42. AASLD IDSA HCV Guidance Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus Hepatology 2015 [Epub ahead of print]
43. EASL recommendations on treatment of hepatitis C 2015 J Hepatol 63 2015 199 236